EGFR and neoplasm: The tumor cells did not show any driver mutations in EGFR, ALK, and ROS1. Immunohistochemical analysis of programmed cell death receptor ligand 1 (22C3) showed highly positive staining (Tumor Proportion Score > 95%) (Fig. 1e).